Faslodex Observations During Regular Use by Advanced Mammacarcinoma Patients
Phase 4
18 Years
N/A
18 Years
N/A
Not Enrolling
Female
Breast Cancer
Female
Breast Cancer
Trial Information
Faslodex Observations During Regular Use by Advanced Mammacarcinoma Patients
Inclusion Criteria:
- Postmenopausal
- Locally advanced or metastatic hormone sensitive breast cancer with known estrogen
receptor (ER) and progesterone receptor (PR) status
- Patient had a recurrence during or after adjuvant anti-oestrogen treatment or
progression of the disease during anti-oestrogen treatment
Exclusion Criteria:
- Life threatening metastases
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Principal Investigator
AstraZeneca Netherlands Medical Director, MD
Investigator Role:
Study Director
Investigator Affiliation:
AstraZeneca
Authority:
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Study ID:
D6997-NL-001
NCT ID:
NCT00241462
Start Date:
June 2005
Completion Date:
December 2009
Related Keywords:
- Breast Cancer
- Advanced Breast Cancer
- Breast Neoplasms
Name | Location |
|---|
